CiTE antibody for AML

To cite or not to cite.

Cite as:

Building products for Google-scale presents some unique challenges in the software development and operational spheres. Through exploring techniques relating to design, development, configuration, deployment and monitoring the talk will describe how Google delivers high availability products with low latency to millions of customers worldwide. Profile. Ollie Cook is a site reliability manager a...

To Cite or Not to Cite: A Note of Annoyance

Sociologists often talk about the “reward” system in science and scholarship. Publication of papers, especially in prestigious journals, adds to an author’s credits. When an author’s work contributes to your own work he is entitled to some “reward” for adding to the world’s knowledge. These rewards are usually given in the form of reference citations. This is, of course, an over-simplification,...

Reasons for treating secondary AML as de novo AML.

In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-rela...

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

CD37 is a tetraspanin expressed on malignant B cells. Recently, CD37 has gained interest as a therapeutic target. We developed AGS67E, an antibody-drug conjugate that targets CD37 for the potential treatment of B/T-cell malignancies. It is a fully human monoclonal IgG2 antibody (AGS67C) conjugated, via a protease-cleavable linker, to the microtubule-disrupting agent monomethyl auristatin E (MMA...